Unum Therapeutics Inc. (UMRX) Tops Q2 EPS by 4c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. SPY
8. AAPL
9. LITE
10. NVT

Go back to Unum Therapeutics Inc. (UMRX) Tops Q2 EPS by 4c, Revenues Miss

Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

August 13, 2018 4:05 PM EDT

IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Active; Expect to Initiate Phase I Trial by End of 2018

CAMBRIDGE, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, today reported financial results and provided a corporate update for the second quarter ended June 30, 2018 and recent activities.

In our first full quarter as a public... More